Processing

Please wait...

Settings

Settings

Goto Application

1. WO2006048727 - PIPERAZINYLPHENALKYL LACTAM/AMINE LIGANDS FOR THE 5HT1B RECEPTOR

Publication Number WO/2006/048727
Publication Date 11.05.2006
International Application No. PCT/IB2005/003252
International Filing Date 21.10.2005
Chapter 2 Demand Filed 25.11.2005
IPC
A61K 31/4166 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4166having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
C07D 233/70 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
233Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
54having two double bonds between ring members or between ring members and non-ring members
66with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
70One oxygen atom
A61P 25/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07D 239/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
06having one double bond between ring members or between a ring member and a non-ring member
08with hetero atoms directly attached in position 2
10Oxygen or sulfur atoms
A61K 31/513 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
C07D 235/26 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
235Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
02condensed with carbocyclic rings or ring systems
04Benzimidazoles; Hydrogenated benzimidazoles
24with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
26Oxygen atoms
CPC
C07D 209/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
04Indoles; Hydrogenated indoles
08with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 209/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
44Iso-indoles; Hydrogenated iso-indoles
46with an oxygen atom in position 1
C07D 209/48
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
44Iso-indoles; Hydrogenated iso-indoles
48with oxygen atoms in positions 1 and 3, e.g. phthalimide
C07D 209/66
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
56Ring systems containing three or more rings
58[b]- or [c]-condensed
62Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
66with oxygen atoms in positions 1 and 3
C07D 217/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
217Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
02with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
04with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 217/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
217Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
22with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
24Oxygen atoms
Applicants
  • PFIZER PRODUCTS INC. [US]/[US] (AllExceptUS)
  • BUTLER, Todd, William [US]/[US] (UsOnly)
Inventors
  • BUTLER, Todd, William
Agents
  • FULLER, Grover, F., Jr.
Priority Data
60/624,29102.11.2004US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PIPERAZINYLPHENALKYL LACTAM/AMINE LIGANDS FOR THE 5HT1B RECEPTOR
(FR) LIGANDS DE LATAME/AMINE PIPERAZINYLPHENALKYLE POUR LE RECEPTEUR 5HT1B
Abstract
(EN) The present invention relates to novel derivatives, that are compounds of Formula (I), wherein R1, R2, R3, R14, X, Y, n and m are defined herein, their pharmaceutically acceptable salts, pharmaceutical compositions and methods using said compounds in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, antagonists of 5-HT1B are useful.
(FR) Nouveaux dérivés, qui sont des composés de formule (I), dans laquelle R1, R2, R3, R14, X, Y, n et m sont tels que définis dans le descriptif, leurs sels pharmaceutiquement acceptables, compositions pharmaceutiques et procédés utilisant de tels composés dans le traitement et la prévention de la dépression, de l'anxiété, du trouble obsessionnel-compulsif (OCD) et d'autres troubles pour lesquels on utilise des antagonistes sélectifs, des agonistes inverses et des agonistes partiels de récepteurs de la sérotonine 1 (5-HT1), des antagonistes de récepteurs 5-HT1B.
Latest bibliographic data on file with the International Bureau